Security Snapshot

Bicara Therapeutics Inc. - COMMON STOCK (BCAX) Institutional Ownership

CUSIP: 055477103

13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

140

Shares (Excl. Options)

57,096,017

Price

$16.83

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / COMMON STOCK
Symbol
BCAX on Nasdaq
Shares outstanding
65,403,762
Price per share
$19.89
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
57,096,017
Total reported value
$960,809,333
% of total 13F portfolios
0%
Share change
+6,913,932
Value change
+$119,906,754
Number of holders
140
Price from insider filings
$19.89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • BCAX - Bicara Therapeutics Inc. - COMMON STOCK is tracked under CUSIP 055477103.
  • 140 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 140 to 7 between Q4 2025 and Q1 2026.
  • Reported value moved from $960,809,333 to $269,220.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 140 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 055477103?
CUSIP 055477103 identifies BCAX - Bicara Therapeutics Inc. - COMMON STOCK in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Bicara Therapeutics Inc. - COMMON STOCK (BCAX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 12% $123,100,386 7,279,739 RA Capital Management, L.P. 26 Feb 2026
T. Rowe Price Investment Management, Inc. 10% +70% $131,386,982 +$67,012,079 6,605,780 +104% T. Rowe Price Investment Management, Inc. 31 Mar 2026
Invus Global Management, LLC 9.6% $50,656,769 5,216,969 Raymond Debbane 30 Jun 2025
Vestal Point Capital, LP 6.5% -30% $62,669,750 -$24,980,250 3,575,000 -28% Vestal Point Capital, LP 31 Dec 2025
FMR LLC 6.1% +20% $56,333,763 +$9,946,631 3,347,223 +21% FMR LLC 31 Dec 2025
Deep Track Capital, LP 5% $48,207,500 2,750,000 Deep Track Capital, LP 05 Feb 2026

As of 31 Dec 2025, 140 institutional investors reported holding 57,096,017 shares of Bicara Therapeutics Inc. - COMMON STOCK (BCAX). This represents 87% of the company’s total 65,403,762 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Bicara Therapeutics Inc. - COMMON STOCK (BCAX) together control 78% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 11% 6,955,993 0% 1.2% $117,069,362
Siren, L.L.C. 8% 5,216,969 0% 2.6% $87,801,588
Vestal Point Capital, LP 5.5% 3,575,000 -30% 2.2% $60,167,250
FMR LLC 5.1% 3,347,223 +24% 0% $56,333,763
T. Rowe Price Investment Management, Inc. 4.9% 3,236,595 +596% 0.03% $54,472,000
RED TREE MANAGEMENT, LLC 4.8% 3,170,509 0% 49% $53,359,666
TPG GP A, LLC 4.6% 3,010,425 0% 1.9% $50,665,453
JANUS HENDERSON GROUP PLC 4% 2,646,285 0.02% $44,484,051
Deep Track Capital, LP 4% 2,614,004 +7.7% 1% $43,993,687
BlackRock, Inc. 3.9% 2,528,451 +9.4% 0% $42,553,826
Omega Fund Management, LLC 3.4% 2,204,650 0% 13% $37,104,260
VANGUARD GROUP INC 3.3% 2,186,150 -0.67% 0% $36,792,904
STATE STREET CORP 2.5% 1,649,537 +179% 0% $27,761,708
FRANKLIN RESOURCES INC 2.5% 1,620,025 0.01% $27,265,020
PRICE T ROWE ASSOCIATES INC /MD/ 2.4% 1,559,535 -11% 0% $26,248,000
GEODE CAPITAL MANAGEMENT, LLC 1.2% 811,400 -2.4% 0% $13,658,764
CITADEL ADVISORS LLC 1.2% 772,258 0.01% $12,997,102
FIL Ltd 1.2% 758,493 -5.6% 0.01% $12,765,437
ACORN CAPITAL ADVISORS, LLC 0.98% 643,382 0% 3.7% $10,828,113
Aisling Capital Management LP 0.87% 568,919 0% 2% $9,574,907
GOLDMAN SACHS GROUP INC 0.84% 552,331 +137% 0% $9,295,731
MILLENNIUM MANAGEMENT LLC 0.66% 434,699 -57% 0.01% $7,315,984
Rock Springs Capital Management LP 0.66% 429,095 +16% 0.37% $7,221,669
Ensign Peak Advisors, Inc 0.61% 401,444 0.01% $6,756,303
NAN FUNG TRINITY (HK) LTD 0.57% 372,385 -3.2% 0.5% $6,267,240

Institutional Holders of Bicara Therapeutics Inc. - COMMON STOCK (BCAX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 13,533 $269,220 -$50,979 $19.89 7
2025 Q4 57,096,017 $960,809,333 +$119,906,754 $16.83 140
2025 Q3 49,994,786 $789,088,187 +$2,780,392 $15.79 112
2025 Q2 51,165,684 $475,330,436 -$6,689,372 $9.29 105
2025 Q1 48,567,553 $633,357,650 +$9,523,679 $13.03 92
2024 Q4 46,709,070 $813,618,424 +$73,899,338 $17.42 84
2024 Q3 36,408,664 $927,393,381 +$849,110,088 $25.47 69

Sponsored